Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results

NANJING, China, Aug. 10, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2012.

Highlights

  • Total revenue was RMB528.7 million (US$83.2 million) for the second quarter of 2012, compared to RMB546.4 million for the same period in 2011, representing a decrease of 3.2%. For the first six months of 2012, total revenue was RMB1,016.3 million (US$160.0 million), representing a decrease of 1.2% from RMB1,028.6 million for the same period in 2011.
  • Gross margin for the second quarter of 2012 was 83.9%, compared to 84.9% for the same period in 2011. For the first six months of 2012, gross margin was 83.0%, compared to 84.4% for the first six months of 2011.
  • Income from operations was RMB41.6 million (US$6.5 million) for the second quarter of 2012, compared to RMB79.9 million for the same period in 2011, representing a decrease of 48.0%. For the first six months of 2012, income from operations was RMB84.8 million (US$13.4 million), which represented a decrease of 22.6% from RMB109.6 million for the same period in 2011.
  • Net income attributable to Simcere was RMB27.0 million (US$4.2 million) for the second quarter of 2012, a decrease of 63.4% from RMB73.7 million for the same period in 2011. For the first six months of 2012, net income attributable to Simcere was RMB55.6 million (US$8.8 million), which represented a decrease of 45.3% from RMB101.6 million for the same period in 2011.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group said, "In the second quarter of 2012, Simcere's revenue and gross margin remained largely stable. While sales of edaravone, Endu and Sinofuan continued to grow compared with the first quarter of 2012, year-over-year sales performance was below our expectation. During the quarter, we increased our marketing efforts for branded generic drugs such as Zailin, Yingtaiqing and Biqi which helped drive sales growth in these key products but impacted profitability."

"In the second quarter, we were encouraged by sales of our new Category 1 drug Iremod and Shanghai Celgen's biogeneric drug Qiangke," continued Mr. Ren. "We also received approval to initiate clinical studies for our oncology drug candidate Thiophenib and continue to see strong progress with the four additional new drug candidates currently under clinical trials."

2012 Second Quarter Financial Results

Total revenue for the second quarter of 2012 was RMB528.7 million (US$83.2 million), compared to RMB546.4 million for the same period in 2011, representing a decrease of 3.2%. For the first six months of 2012, total revenue was RMB1,016.3 million (US$160.0 million), representing a decrease of 1.2% from RMB1,028.6 million for the same period in 2011.

The tables below set forth the Company's top 10 products by revenue for the three months ended June 30, 2012 and six months ended June 30, 2012:

In Thousands




Three months ended June 30, 2012


Three months ended June 30, 2011





RMB


USD


% of total


RMB


% of total

Change

Products

Therapeutic Area






revenue




revenue


Edaravone

Neuroscience


177,825


27,991


33.6%


217,934


39.90%

(18.4%)

Endu

Oncology


66,779


10,511


12.6%


70,021


12.80%

(4.6%

Zailin

Infectious Disease


61,630


9,701


11.7%


43,762


8.00%

40.8%

Yingtaiqing

Inflammation


43,928


6,915


8.3%


45,909


8.40%

(4.3%)

Sinofuan

Oncology


41,683


6,561


7.9%


52,974


9.70%

(21.3%)

Biqi

Gastroenterology


26,812


4,220


5.1%


19,689


3.60%

36.2%

Jiebaishu

Oncology


19,507


3,071


3.7%


16,438


3.00%

18.7%

Anqi

Infectious Disease


14,881


2,342


2.8%


18,043


3.30%

(17.5%)

Anxin

Infectious Disease


14,775


2,326


2.8%


14,371


2.60%

2.8%

Kechuanning

Respiratory


10,672


1,680


2.0%


10,453


1.90%

2.1%

Others



50,242


7,908


9.5%


36,769


6.80%

36.6%

Total



528,734


83,226


100.0%


546,363


100.00%

(3.2%)











































Six months ended June 30, 2012


Six months ended June 30, 2011





RMB


USD


% of total


RMB


% of total

Change

Products

Therapeutic Area






revenue




revenue


Edaravone

Neuroscience


338,728


53,318


33.3%


406,662


39.50%

(16.7%)

Endu

Oncology


123,128


19,381


12.1%


119,656


11.60%

2.9%

Zailin

Infectious Disease


121,662


19,150


12.0%


105,245


10.20%

15.6%

Sinofuan

Oncology


80,973


12,746


8.0%


82,355


8.00%

(1.7%)

Yingtaiqing

Inflammation


77,075


12,132


7.6%


86,635


8.40%

(11.0%)

Biqi

Gastroenterology


48,720


7,669


4.8%


41,816


4.10%

16.5%

Jiebaishu

Oncology


34,734


5,467


3.4%


29,820


2.90%

16.5%

Anqi

Infectious Disease


30,655


4,825


3.0%


34,910


3.40%

(12.2%)

Anxin

Infectious Disease


30,289


4,768


3.0%


25,668


2.50%

18.0%

Kechuanning

Respiratory


24,542


3,863


2.4%


23,960


2.30%

2.4%

Others



105,837


16,659


10.4%


71,838


7.10%

47.3%

Total



1,016,343


159,978


100.0%


1,028,565


100.00%

(1.2%)

For more information about the above products, please visit our corporate website: www.simcere.com.

Gross margin for the second quarter of 2012 was 83.9%, compared to 84.9% for the same period in 2011. For the first six months of 2012, gross margin was 83.0%, compared to 84.4% for the first six months of 2011.

Research and development expenses for the second quarter of 2012 totaled RMB55.0 million (US$8.7 million), which represented an increase of 36.9% from RMB40.1 million for the same period in 2011. This increase was due primarily to the increased expenditure on on-going research and development projects, as well as a reduction of RMB5.5 million in government research and development grants recognized compared with the same period in 2011. As a percentage of total revenue, research and development expenses increased to 10.4% for the second quarter of 2012 from 7.3% for the same period in 2011. For the first six months of 2012, research and development expenses totaled RMB103.2 million (US$16.3 million), compared to RMB82.7 million for the same period in 2011.

Sales, marketing and distribution expenses for the second quarter of 2012 were RMB291.4 million (US$45.9 million), which represented an increase of 0.9% from RMB288.9 million for the same period in 2011. As a percentage of total revenue, sales, marketing and distribution expenses increased to 55.1% for the second quarter of 2012 from 52.9% for the same period in 2011. This increase was due primarily to increased spending on promotional activities for branded generic pharmaceutical products, such as Zailin, Yingtaiqing and Biqi. For the first six months of 2012, sales, marketing and distribution expenses were RMB550.2 million (US$86.6 million), which represented a decrease of 0.6% from RMB553.3 million for the same period in 2011.   

General and administrative expenses were RMB55.7 million (US$8.8 million) for the second quarter of 2012, which represented a decrease of 25.3% from RMB74.7 million for the same period in 2011. As a percentage of total revenue, general and administrative expenses decreased to 10.5% for the second quarter of 2012 from 13.7% for the same period in 2011. For the first six months of 2012, general and administrative expenses were RMB120.8 million (US$19.0 million), which represented a decrease of 15.4% from RMB142.8 million for the same period in 2011.

Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB2.7 million (US$0.4 million) for the second quarter of 2012. Share-based compensation expenses for the second quarter of 2011 were RMB7.8 million. The decrease was primarily due to the expiration of the first and second batches of restricted shares. For the first six months of 2012, share-based compensation expenses totaled RMB6.5 million (US$1.0 million), which represented a decrease of 56.7% from RMB15.1 million for the same period in 2011.

Income from operations was RMB41.6 million (US$6.5 million) for the second quarter of 2012, representing a decrease of 48.0% from RMB79.9 million for the same period in 2011, which was primarily due to a decrease in revenue. The Company recorded other operating income of RMB20.0 million in the second quarter of 2011 in connection with the settlement with former shareholders of Jiangsu Quanyi Biological Technology Stock Co., Ltd ("Jiangsu Quanyi") regarding the Company's 2009 acquisition of a 37.5% equity interest in Jiangsu Quanyi. For the first six months of 2012, income from operations was RMB84.8 million (US$13.4 million), which represented a decrease of 22.6% from RMB109.6 million for the same period in 2011.

Income tax expense for the second quarter of 2012 was RMB0.3 million (US$0.04 million), compared to income tax expense of RMB0.7 million for the same period in 2011. For the first six months of 2012, income tax expense was RMB2.9 million (US$0.5 million), compared to RMB5.8 million for the same period in 2011.

Net income attributable to Simcere was RMB27.0 million (US$4.2 million) for the second quarter of 2012, compared to RMB73.7 million for the same period in 2011. Net margin, representing net income attributable to Simcere divided by total revenue, was 5.1% for the second quarter of 2012, compared to 13.5% for the same period in 2011. For the first six months of 2012, net income attributable to Simcere was RMB55.6 million (US$8.8 million), which represented a decrease of 45.3% from RMB101.6 million for the same period in 2011. Net margin for the first six months of 2012 was 5.5%, compared to 9.9% for the same period in 2011.

Basic and diluted earnings per American Depository Share ("ADS") for the second quarter of 2012 were RMB0.50 (US$0.08) and RMB0.50 (US$0.08), respectively. Basic and diluted earnings per ADS for the first six months of 2012 were RMB1.03 (US$0.16) and RMB1.03 (US$0.16), respectively. One ADS represents two ordinary shares of the Company.

As of June 30, 2012, the Company had cash, cash equivalents and restricted cash of RMB288.7 million (US$45.4 million), compared to RMB262.6 million as of December 31, 2011.

Financial Information

The preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call

Simcere Pharmaceutical Group will host a conference call to discuss the Company's results for the second quarter of 2012 on Friday, August 10 at 8:00 a.m. Eastern Time (Friday, August 10 at 8:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for the second quarter of 2012 and to answer questions.

To access the conference call, please dial:

International toll:

+65.6723.9381

United States toll-free:

+1.866.519.4004

United States toll:

+1.718.354.1231

China Domestic toll:

800.819.0121

China Domestic mobile toll:

400.620.8038

Hong Kong toll:

+852.2475.0994

Please ask to be connected to Q2 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 15292591.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:

+1.866.214.5335

United States toll:

+1.718.354.1232

The passcode for replay participants is 15292591. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.com

In Nanjing:
Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8857

In the United States:
Cindy Zheng
Brunswick Group
Tel: 1-212-333-3810

 

In Beijing:
Yue Yu
Brunswick Group
Tel: 86-10-5960-8600

 

In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000 

 

SIMCERE PHARMACEUTICAL GROUP
PRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(AMOUNTS EXPRESSED IN THOUSANDS, EXCEPT SHARE AND ADS DATA)


Three months ended June 30,


Six months ended June 30,


2011

2012

2012


2011

2012

2012


RMB

RMB

USD


RMB

RMB

USD

Product revenue

546,363

528,734

83,226


1,028,565

1,016,343

159,978

Total revenue

546,363

528,734

83,226


1,028,565

1,016,343

159,978

Cost of materials and production

(82,761)

(85,115)

(13,398)


(160,234)

(172,953)

(27,223)

Gross profit

463,602

443,619

69,828


868,331

843,390

132,755









Operating expenses:








Research and development

(40,147)

(54,956)

(8,650)


(82,729)

(103,242)

(16,251)

Sales, marketing and distribution

(288,855)

(291,366)

(45,863)


(553,250)

(550,158)

(86,598)

General and administrative

(74,661)

(55,740)

(8,774)


(142,798)

(120,822)

(19,018)

Other operating income

20,000

-

-


20,000

15,650

2,463

Income from operations

79,939

41,557

6,541


109,554

84,818

13,351









Interest income

1,310

1,180

186


2,362

2,041

321

Interest expense

(10,001)

(19,669)

(3,096)


(19,405)

(39,862)

(6,274)

Foreign currency exchange gains (losses)

2,142

(546)

(86)


3,717

(603)

(95)

Other  income

1,099

108

17


7,522

4,189

659

 

Equity in losses of equity method affiliated

company

(3,427)

(2,383)

(375)


(6,599)

(4,926)

(775)

Earnings  before income taxes

 

71,062

20,247

3,187


97,151

45,657

7,187









Income tax expense

(711)

(256)

(40)


(5,802)

(2,893)

(456)

Net Income           

70,351

19,991

3,147


91,349

42,764

6,731









Less: Net loss attributable to the noncontrolling interest

3,355

6,983

1,099


10,247

12,834

2,020

Net income attributable to Simcere

73,706

26,974

4,246


101,596

55,598

8,751









Earnings  per share attributable to Simcere:








Basic

0.69

0.25

0.04


0.95

0.51

0.08

Diluted

0.67

0.25

0.04


0.92

0.51

0.08









Earnings  per ADS attributable to Simcere:








Basic

1.38

0.50

0.08


1.90

1.03

0.16

Diluted

1.33

0.50

0.08


1.84

1.03

0.16









Weighted average number of common shares: Basic

106,903,665

107,834,280

107,834,280


106,857,024

108,136,224

108,136,224

Diluted

110,578,606

107,961,891

107,961,891


110,501,057

108,329,408

108,329,408






 

 

SIMCERE PHARMACEUTICAL GROUP
PRELIMINARY UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(AMOUNTS EXPRESSED IN THOUSANDS)


December 31,

June 30,

June 30,


2011

RMB

2012

RMB

2012

USD





Assets




Current assets




Cash, cash equivalents and restricted cash

262,557

288,671

45,439

Bills receivable

814,822

632,564

99,569

Accounts receivable, net

462,050

421,883

66,407

Inventories

126,708

124,392

19,580

Other current assets

181,196

185,411

29,185

Total current assets

1,847,333

1,652,921

260,180

Property, plant and equipment, net

925,815

905,436

142,521

Land use rights

139,707

138,106

21,739

Goodwill and intangible assets, net

648,408

631,394

99,385

Investments in and advance to an affiliated company                        

91,355

86,857

13,672

Other non-current assets

81,499

89,401

14,072

Total assets

3,734,117

3,504,115

551,569

Liabilities




Current liabilities




Short-term borrowings and current portion of long-term borrowings

816,150

755,000

118,842

Accounts payable

52,191

40,782

6,419

Bills payable

28,379

20,000

3,148

Other payables and accrued liabilities

565,827

429,067

67,538

Total current liabilities

1,462,547

1,244,849

195,947

Long-term borrowings, excluding current portion

-

2,000

315

Deferred tax liabilities

46,248

43,751

6,887

Other liabilities

31,625

32,141

5,059

Total liabilities

1,540,420

1,322,741

208,208

Shareholders' equity




Simcere shareholders' equity




Ordinary shares at par

8,532

8,401

1,322

Additional paid-in capital

954,750

899,850

141,642

Accumulated other comprehensive loss

(104,608)

(104,384)

(16,431)

Retained earnings

1,197,507

1,252,825

197,202

Total equity attributable to Simcere

2,056,181

2,056,692

323,735

Noncontrolling interest

137,516

124,682

19,626

Total shareholders' equity

2,193,697

2,181,374

343,361

Commitments and contingencies




Total liabilities and shareholders' equity

 

3,734,117

3,504,115

551,569

Note: The conversions of Renminbi (RMB) into United States dollars (USD) as at the reporting dates are based on the noon buying rate of USD1.00 = RMB6.3530 on June 30, 2012 as set forth in the H. 10 statistical release of the Federal Reserve Board. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on the reporting dates.

 

SOURCE Simcere Pharmaceutical Group



RELATED LINKS
http://www.simcere.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.